Sandoz

Sandoz has received market approval in Canada for a generic version of the diabetes drug semaglutide, authorized as a weekly injection for adult patients with type 2 diabetes. The Canadian market for GLP‑1 drugs is estimated at around $2.6 billion and includes roughly 12 million semaglutide injection pens annually. Sandoz also reports approval in Brazil and is studying a tirzepatide generic in the US; the Canadian approval does not affect its 2026 guidance. » Plus sur finanzen.net

Sandoz shares rose 4.4% to CHF 71.22 after the company unveiled its long-term “Bio100” initiative, aiming to expand its biosimilar portfolio from 13 to more than 100 products by 2040 and to increase market coverage to around 80% by 2035. For 2025–2030 Sandoz targets annual net sales growth in the mid- to high-single-digit range and an adjusted EBITDA margin of 25–27% by 2030; by 2035 it aims to double net sales and achieve a margin above 30%. To support the strategy, Sandoz announced an investment in a new biosimilar active pharmaceutical ingredient manufacturing site in Ljubljana, Slovenia. Analysts had already issued positive assessments with price targets of CHF 75–80, helping push the stock toward its 52-week high. » Plus sur de.investing.com

Sandoz plans to more than double revenue by 2035 by expanding its biosimilar portfolio and targets a core EBITDA margin of over 30% (excluding GLP-1 effects). By 2040 the portfolio should grow to more than 100 biosimilars (currently 13) and market coverage for expiring patents should rise to around 80% by 2035. For 2025–2030 the company expects average annual net sales growth in the mid- to high-single-digit range at constant exchange rates and a core EBITDA margin of 25–27% (including GLP-1). Sandoz also confirmed its existing mid-term outlook through 2028; net sales for 2025 were $11.1 billion. » Plus sur de.investing.com